Pyxis Oncology (PYXS) said late Thursday it will focus its resources on advancing its lead clinical program, PYX-201, as part of its portfolio prioritization plan.
The clinical-stage drugmaker said PYX-201 showed "significant RECIST responses" in head and neck squamous cell carcinoma as well as "additional potential in other solid tumors."
Pyxis said it will suspend further clinical investment in its second clinical program, PYX-106, to allocate resources for PYX-201. PYX-106 was in-licensed from Biosion, with Biosion retaining rights for Greater China.
The company also said its cash position is expected to fund its planned trials of PYX-201 into H2 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。